参考文献/References:
[1] Kurdistani SK. Histone modifications in cancer biology and prognosis[M].Epigenetics and Disease. Springer Basel, 2011: 91-106.
[2] Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy[J].Cell, 2012,150(1):12-27.
[3] Russo D, Damante G, Puxeddu E, et al. Epigenetics of thyroid Cancer and novel therapeutic targets[J].J Mol Endocrinol, 2011,46(3):R73-R81.
[4] Weichert W, Roske A, Niesporek S, et al. Class Ⅰ histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class Ⅰ histone deacetylases in vitro and in vivo[J].Clin Cancer Res, 2008,14(6):1669-1677.
[5] Seligson DB, Horvath S, Mcbrian MA, et al. Global levels of histone modifications predict prognosis in different cancers[J].Am J Pathol, 2009,174(5):1619-1628.
[6] Mosashvilli D, Kahl P, Mertens C, et al. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma[J].Cancer Sci, 2010,101(12):2664-2669.
[7] Puppin C, Passon N, Lavarone E, et al. Levels of histone acetylation in thyroid tumors[J].Biochem Biophys Res Commun, 2011,411(4):679-683.
[8] Poke FS, Qadi A, Holloway AF. Reversing aberrant methylation patterns in Cancer[J].Curr Med Chem, 2010,17(13):1246-1254.
[9] Kondo T, Nakazawa T, Ma D, et al. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas[J].Lab Invest,2009,89(7):791-799.
[10] Lavarone E, Puppin C, Passon N, et al. The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid Cancer cell lines[J].Mol Cell Endocrinol, 2013,365(1):1-10.
[11] Moss TJ, Wallrath LL. Connections between epigenetic gene silencing and human disease[J].Mutat Res, 2007,618(1-2):163-174.
[12] Pérez-Cadahía B, Drobic B, Khan P, et al. Current understanding and importance of histone phosphorylation in regulating chromatin biology[J].Curr Opin Drug Discov Devel, 2010,13(5):613-622.
[13] Du HN. Transcription, DNA damage and beyond: the roles of histone ubiquitination and deubiquitination[J].Curr Protein Pept Sci, 2012,13(5):447-466.
[14] Mcginty RK, Kim J, Chatterjee C, et al. Chemically ubiquitylated histone H2B stimulates hDot1L-mediated intranucleosomal methylation[J].Nature, 2008,453(7196):812-816.
[15] Nakagawa T, Kajitani T, Togo S, et al. Deubiquitylation of histone H2A activates transcriptional initiation via trans-histone cross-talk with H3K4 di- and trimethylation[J].Genes Dev, 2008,22(1):37-49.
[16] Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets[J].Gastroenterology, 2004,127(5 Suppl 1):S51-S55.
[17] Agboola A, Musa AA, Ayoade BA, et al. Clinicopathological and molecular significance of Sumolyation marker(ubiquitin conjugating enzyme 9(UBC9))expression in breast Cancer of black women[J].Pathol Res Pract, 2014,210(1):10-17.
[18] Wang L, Banerjee S. Differential PIAS3 expression in human malignancy[J].Oncol Rep,2004,11(6):1319-1324.
[19] Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid Cancer cells by targeting major signaling pathways[J].J Clin Endocrinol Metab, 2010,95(2):820-828.
[20] 袁耿彪,匡安仁,范群,等. 维甲酸联合曲古抑素对甲状腺癌细胞的诱导分化作用[J].癌症, 2010,29(4):415-421.
[21] 包建东, 林秀峰, 俞惠新, 等. 曲古菌素 A 对甲状腺癌细胞 NIS 基因表达和摄碘功能的影响[J].中华核医学杂志, 2010(2): 116-119.
[22] Pugliese M, Fortunati N, Germano A, et al. Histone deacetylase inhibition affects Sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid Cancer cells[J].Thyroid, 2013,23(7):838-846.
[23] Catalano MG,Fortunati N,Pugliese M,et al. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid Cancer cells[J].J Clin Endocrinol Metab, 2012,97(7):E1150-E1159.
[24] Mitmaker EJ, Griff NJ, Grogan RH, et al. Modulation of matrix metalloproteinase activity in human thyroid Cancer cell lines using demethylating agents and histone deacetylase inhibitors[J].Surgery, 2011,149(4):504-511.
[25] 孙珂,刘纯. 苯丁酸钠对甲状腺滤泡癌细胞侵袭能力及MMP-9和TIMP-1表达的影响[J].中国肿瘤生物治疗杂志, 2009,16(1):67-70.
[26] Zuo H, Gandhi M, Edreira MM, et al. Downregulation of rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors[J].Cancer Res,2010,70(4):1389-1397.
[27] Altmann A, Eisenhut M, Bauder-Wüst U, et al. Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275[J].Eur J Nucl Med Mol Imaging,2010,37(12):2286-2297.
[28] Xiao X, Ning L, Chen H. Notch1 mediates growth suppression of papillary and follicular thyroid Cancer cells by histone deacetylase inhibitors[J].Mol Cancer Ther,2009,8(2):350-356.
[29] Adler JT, Hottinger DG, Kunnimalaiyaan M, et al. Inhibition of growth in medullary thyroid Cancer cells with histone deacetylase inhibitors and Lithium chloride[J].J Surg Res,2010,159(2):640-644.
[30] Ellis L, Atadja PW, Johnstone RW. Epigenetics in Cancer: targeting chromatin modifications[J].Mol Cancer Ther, 2009,8(6):1409-1420.
相似文献/References:
[1]叶婷婷,董艳.表观遗传学在子代代谢性疾病发生中的作用[J].国际内分泌代谢杂志,2014,(01):60.[doi:10.3760/cma.j.issn.1673-4157.2014.01.017]
Ye Tingting,Dong Yan.Role of epigenetics in the development of metabolic diseases in offsprings[J].International Journal of Endocrinology and Metabolism,2014,(05):60.[doi:10.3760/cma.j.issn.1673-4157.2014.01.017]
[2]李兴佳,徐书杭,刘超.雌激素及其受体与甲状腺癌的关系[J].国际内分泌代谢杂志,2016,36(04):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
Li Xingjia,Xu Shuhang,Liu Chao.Relationship between estrogen, its receptors and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2016,36(05):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
[3]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[4]郑仁东,刘超.STAT3与甲状腺肿瘤[J].国际内分泌代谢杂志,2017,37(05):345.
Zheng Rendong,Liu Chao..STAT3 and thyroid tumor[J].International Journal of Endocrinology and Metabolism,2017,37(05):345.
[5]孟祥慧 徐书杭 陈国芳 刘超.二甲双胍在甲状腺癌防治中的作用[J].国际内分泌代谢杂志,2018,38(04):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
Meng Xianghui*,Xu Shuhang,Chen Guofang,et al.Role of metformin in prevention and treatment of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2018,38(05):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
[6]曹星月 武晓泓.基因拷贝数异常在甲状腺癌诊断和预后判断中的
应用进展[J].国际内分泌代谢杂志,2019,39(01):29.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
Cao Xingyue,Wu Xiaohong.Progress in the application of gene copy number variations in diagnosis and prognosis of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2019,39(05):29.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
[7]张会峰 胡天赤 陈学勤 叶向荣 刘超.丙型肝炎病毒感染与自身免疫性甲状腺疾病
及甲状腺癌风险[J].国际内分泌代谢杂志,2019,39(02):128.[doi:10.3760/cma.j.issn.1673-4157.2019.02.014]
Zhang Huifeng,Hu Tianchi,Chen Xueqin,et al.Relationship between hepatitis C virus infection and the risk of autoimmune thyroid diseases and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2019,39(05):128.[doi:10.3760/cma.j.issn.1673-4157.2019.02.014]
[8]张玉洁 孟召伟 章明放 宋丽丽 李宁.甲状腺疾病的代谢组学研究现状[J].国际内分泌代谢杂志,2019,39(03):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
Zhang Yujie,Meng Zhaowei,Zhang Mingfang,et al.Research status of metabolomics in thyroid diseases[J].International Journal of Endocrinology and Metabolism,2019,39(05):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
[9]田勍,洪天配.甲状腺结节诊治过程中的难点与应对[J].国际内分泌代谢杂志,2021,41(06):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
Tian Qing,Hong Tianpei..Difficulties and countermeasures in the diagnosis and treatment of thyroid nodules[J].International Journal of Endocrinology and Metabolism,2021,41(05):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
[10]张雅,相萍萍,徐书杭,等.经皮无水乙醇注射治疗甲状腺结节:老方法的新认识[J].国际内分泌代谢杂志,2022,42(06):469.[doi:10.3760/cma.j.cn121383-20210926-09075]
Zhang Ya,Xiang Pingping,Xu Shuhang,et al.Percutaneous ethanol ablation for thyroid nodules: new perspectives on an old paradigm[J].International Journal of Endocrinology and Metabolism,2022,42(05):469.[doi:10.3760/cma.j.cn121383-20210926-09075]